Saturday 17 October 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7% and free cash flow grew 3.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
35.96
0.61
−1.67%
Follow MDLN
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/S ratio |
1.14 | 1.27 | 0.00 | 0.00 |
+3 more quarters Free account |
P/FCF ratio |
14.67 | 15.96 | 10.06 | 0.00 | |
P/Operating CF |
47.27 | 88.46 | 19.51 | 0.00 | |
P/B ratio |
1.77 | 1.88 | 1.76 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.47 | 1.63 | 0.00 | 0.00 | |
EV/EBITDA |
4.35 | 4.58 | 0.00 | 0.00 | |
EV/Operating CF |
14.24 | 15.41 | 10.16 | 3.76 | |
EV/FCF |
18.97 | 20.48 | 13.20 | 4.66 | |
Quick Ratio |
2.34 | 2.33 | 2.20 | — | |
Current Ratio |
4.33 | 4.41 | 4.29 | — | |
Net Debt/EBITDA |
14.91 | 15.05 | 1.36 | 0.00 | |
Debt/Assets |
31.96% | 32.22% | 32.64% | 0.00% | |
Debt/Equity |
0.66 | 0.65 | 0.65 | 0.00 | |
Asset Turnover |
1.51 | 0.76 | 0.00 | — | |
Operating CF/Net income |
11.92 | 3.19 | 9.58 | 0.59 | |
Capex/Depreciation |
(0.41) | (0.36) | (0.42) | (0.42) | |
Interest Coverage |
3.32 | 3.10 | — | 2.88 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.85% | 16.70% | 0.00% | 15.58% | |
Intangible Assets out of Total Assets |
0.55 | 0.56 | 0.57 | 0.00 | |
Share Based Compensation of Revenue |
0.38% | 0.31% | 0.00% | 0.22% | |
Graham Net Nets |
(0.25) | (0.23) | (0.25) | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
6.82% | 6.27% | 9.94% | 0.00% | |
Revenue per Share |
8.97 | 8.98 | 9.61 | 0.00 | |
Operating CF per Share |
0.83 | 0.50 | 2.15 | 0.00 | |
Capex per Share |
(0.13) | (0.12) | (0.55) | 0.00 | |
Free Cash Flow per Share |
0.70 | 0.39 | 1.60 | 0.00 | |
Cash per Share |
3.12 | 2.73 | 2.39 | — | |
Shareholders Equity per Share |
22.26 | 23.63 | 23.81 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
22.26 | 23.63 | 23.81 | 0.00 | |
Free Cash Flow |
604.00 | 316.00 | 1,297.00 | 87.00 | |
Working Capital |
9,032.00 | 8,644.00 | 8,189.00 | — | |
Capital Expenditures |
(111.00) | (96.00) | (447.00) | (110.00) | |
Net Current Asset Value |
(8,531.00) | (8,485.00) | (8,519.00) | 0.00 | |
EV/EBIT |
4.73 | 4.97 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.06 | 0.02 | |
Price to Operating Income |
3.66 | 3.87 | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
19,675.00 | 37,496.00 | 19,242.00 | — |
Columns are period end dates